## 17<sup>th</sup> SSNN Congress – 28<sup>th</sup> November 2021

08:45 – 09:00 | Welcome Address | Dafin Muresanu (Romania), Natan Bornstein (Israel), Wolfgang Grisold (Austria), Volker Homberg

Presidential Session - Dafin Muresanu (Romania), Natan Bornstein (Israel)

09:00 – 09:38 Paraneoplastic neuropathies: what's new since the 2004 recommended diagnostic criteria | Wolfgang Grisold (Austria)

09:38 – 10:24 Advances and updates in neurorecovery after stroke – new EAN-EFNR guideline | Dafin Muresanu (Romania)

10:24 - 10:54 Pharmacological aspects on functional recovery in post-acute cerebral injury | Volker Homberg (Germany)

10:54 – 11:15 Novel and non-invasive brain-computer interface-based stimulation device using frequency tuned electromagnetic fields to significantly reduce disability following sub-acute ischemic stroke: A BrainQ technology-pilot randomized controlled trial | Natan Bornstein (Israel)

11:15 – 11:25 Session Break

## Session 2 | Chairpersons - Wolfgang Grisold (Austria), Volker Homberg (Germany)

11:30 – 12:00 Brain/neural-controlled exoskeletons for restoration of movement | Surjo Soekadar (Germany)

12:00 – 12:33 Application of non-invasive brain stimulation for neurorehabilitation | Nam Jong-Paik (South Korea)

12:33 – 13:03 Vagus nerve stimulation for post-stroke motor recovery | Jesse Dowson (UK)

13:03 - 14:00 Lunch Break

## Session 3 | Chairpersons - Surjo Soekadar (Germany), Antonio Federico (Italy)

14:05 – 14:58 Update of Clinical and pathogenetic aspects of inherited small vessel diseases | Antonio Federico (Italy)

14:58 – 15:48 Neurorights, neuromodulation and the neurologic catastrophe of our era | Bogdan Popescu (Romania)

15:48 – 16:18 The impact of N-Pep-12 treatment on brain electrical activity after ischemic stroke | Livia Popa (Romania)

16:18 – 16:28 Session Break

## Session 4 | Chairpersons - David Good (USA), Michael Chopp (USA)

16:33 – 17:15 What will stroke rehabilitation be like in 2030? | David Good (USA)

17:15 – 17:45 Neurotrophic factors – an effective neurovascular therapy for stroke with therapeutic effects mediated by secondary small vesicles, exosomes, generated by cerebral endothelial cells | Michael Chopp (USA)

17:45 – 18:22 Key factors to consider when planning for a large brain stimulation stroke motor recovery trial — an example of TRANSPORT2 | Wayne Feng (USA)

18:22 – 18:48 Cerebellar DBS to Promote Upper Extremity Motor Function in Chronic Stroke - Phase I Trial | Kenneth Baker (USA)

**Concluding Remarks** - Dafin Muresanu (Romania), Natan Bornstein (Israel), Wolfgang Grisold (Austria), Volker Homberg (Germany)